N/A N=38 Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease
PAD
Primary: Change of Ankle Brachial Index (ABI) at 6-month Post-procedure. — 0.24; 0.44 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=85 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Giant Cell Tumor of Bone
Primary: Number of Participants Experiencing Adverse Events (AEs) of Interest (EOI) — 3; 0; 6; 1 Count of Participants
N/A N=655 Brief Video Interventions for Depression
Depressive Symptoms
Primary: Change in the Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR) — 13.67; 14.09; 14.29; 13.79 units on a scale — p=.54
Phase 2 N=90 Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
Opioid Withdrawal
Primary: Subjective Opioid Withdrawal Scale-Gossop (SOWS) Scale Score — 7.0; 9.1 score on a scale — p=.05
Phase 1 N=23 A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
SARS-CoV-2 Infection
Primary: Participants With Adverse Events (AEs) up to 72 Hours Post-dosing — 2; 1; 2 Participants
Phase 2 N=116 Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
Respiratory Syncytial Virus
Primary: Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture — 2.55; 2.84 log10 plaque forming units (PFU)/mL — p=0.578
Phase 2 N=24 QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Chordoma
Primary: Overall Response Rate — 1; 1 Participants
Phase 1 N=12 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
N/A N=189 The OPENS Trial: Offering Women PrEP (Aim 1)
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
N/A N=51 FACT Biomarker Subgroup Analysis
Pre-Eclampsia
Primary: Folate Status — 2701; 2686; 105; 67.1 nmol/L
Phase 1 N=42 A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Change in Mean Glucagon Concentration During Induced Hypoglycemia From Target Plasma Glucose (PG) Concentration of 100 Milligrams Per Deciliter (mg/dL) to a Nadir Target…
N/A N=77,814 Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
Non-valvular Atrial Fibrillation
Primary: Incidence Rate (Per 1,000 Participant-Year) of Composite of Stroke and Systemic Embolism (SE): Balanced Cohorts — 75.227; 55.801 Events Per 1000 Participant-Years…
N/A N=450 Early Venous Reflux Ablation Ulcer Trial
Venous Leg Ulcer
Primary: Time to Ulcer Healing From Date of Randomisation to Date of Healing up to 365 Days — 82; 56 days
Phase 2 N=54 Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities as Measured by NCI CTC v2.0 — 5; 14; 7; 28 Participants
Phase 1 N=28 Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
RSV Infection
Primary: Number of Participants With Unsolicited Treatment Emergent Adverse Events (TEAEs) Through Day 151 — 1; 2; 3; 3 Participants